← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV25행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
ADCLimited DatastaleApproved
Sirolimus (Sirolimus)
Prevail Therapeutics·FRα
143 trials
Overview
Program
Sirolimus
Overview
Company
Prevail Therapeutics
Overview
Modality
ADC
Overview
Target
FRα
Overview
Indication
Parkinson Disease
Overview
Phase
APPROVED
Overview
Status
RECRUITING
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Established
Overview
Approval status
Approved (flag incomplete)
MoA
Mechanism
target synergy, effectively inhibits the PI3K pathway
MoA
Biomarker
biomarkers or targeted therapies to guide management
PK/PD
Species
Pig, Data on prenatal indications, pharmacokinetics, and outcomes remain limited.
PK/PD
Animal (cat.)
In vitro
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Pig, Data on prenatal indications, pharmacokinetics, and outcomes remain limited.
Toxicology
Animal (cat.)
In vitro
Toxicology
Major finding
pneumonitis
Clinical
Safety signal
pneumonitis
Clinical
Selected reported efficacy
21%
Clinical
Result source
ClinicalTrials.gov NCT01783444
Clinical
Program phase
APPROVED
Clinical
Trial activity
No active/completed counts
Clinical
Trial ref
NCT01783444